Trial data keep BioSphere on track for UFE (uterine fibroid embolisation) filing
This article was originally published in Clinica
Executive Summary
BioSphere Medical says it is on track to submit its microspheres for uterine fibroid embolisation (UFE) to the US FDA by the second quarter of 2002, following favourable results from a phase II trial of the product. The product will be aimed at the six million women who seek treatment for uterine fibroids annually in the US.